Biogen Reports Positive Outcomes from Higher-Dose Nusinersen Trial in SMA Treatment
Sep 5, 2024
Biogen Equities
Biogen Announces European Approval for Tocilizumab Biosimilar, TOFIDENCE™
Jun 25, 2024
FDA Approves Eisai's LEQEMBI® Maintenance Dosing Application for Early Alzheimer's Treatment
Jun 10, 2024
European Commission Revokes Marketing Authorizations for Generic TECFIDERA® Variants; Biogen Affected
Dec 20, 2023